5 Value Stocks In The Healthcare Sector
5 Value Stocks In The Healthcare Sector
What is a Value Stock?
什么是价值股?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
传统上,价值股是根据市场上投资者如何估值该公司的未来增长前景来定义的。低市盈率倍数是表明公司被低估的良好基础指标,很可能被贴上价值股的标签。
The following stocks are considered to be notable value stocks in the healthcare sector:
以下股票被认为是医疗保健领域值得注意的价值股票:
- Spok Holdings (NASDAQ:SPOK) - P/E: 8.96
- MEI Pharma (NASDAQ:MEIP) - P/E: 1.53
- Roivant Sciences (NASDAQ:ROIV) - P/E: 2.17
- Agile Therapeutics (NASDAQ:AGRX) - P/E: 0.17
- Exicure (NASDAQ:XCUR) - P/E: 0.34
- Spok Holdings(纳斯达克股票代码:SPOK)——市盈率:8.96
- MEI Pharma(纳斯达克股票代码:MEIP)——市盈率:1.53
- Roivant Sciences(纳斯达克股票代码:ROIV)——市盈率:2.17
- Agile Therapeutics(纳斯达克股票代码:AGRX)——市盈率:0.17
- Exicure(纳斯达克股票代码:XCUR)——市盈率:0.34
Most recently, Spok Holdings reported earnings per share at $0.22, whereas in Q2 earnings per share sat at $0.23. The company's most recent dividend yield sits at 8.6%, which has decreased by 2.22% from 10.82% last quarter.
最近,Spok Holdings公布的每股收益为0.22美元,而第二季度的每股收益为0.23美元。该公司最近的股息收益率为8.6%,较上个季度的10.82%下降了2.22%。
MEI Pharma's earnings per share for Q2 sits at $-1.66, whereas in Q1, they were at 8.46. Roivant Sciences saw an increase in earnings per share from -0.4 in Q2 to $-0.21 now. Agile Therapeutics saw an increase in earnings per share from -3.1 in Q2 to $-1.47 now. This quarter, Exicure experienced an increase in earnings per share, which was $-0.7 in Q1 and is now $-0.68.
MEI Pharma第二季度的每股收益为-1.66美元,而第一季度的每股收益为8.46美元。Roivant Sciences的每股收益从第二季度的-0.4美元增长到现在的-0.21美元。Agile Therapeutics的每股收益从第二季度的-3.1美元增长到现在的-1.47美元。本季度,Exicure的每股收益有所增加,第一季度为-0.7美元,目前为-0.68美元。
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
意义:价值股可能需要一些时间才能从其被低估的位置中反弹。投资价值股的风险在于,这种出现可能永远无法实现。